We are using cookies This website uses cookies in order to offer you the most relevant information. By browsing this website, you accept these cookies.
Primary outcome: We evaluated mean change in blood glycatedhemoglobin levels.
2
Glycemic control was based on glycatedhemoglobin levels and fasting blood glucose test.
3
Measurements and main results: We used admission glycatedhemoglobin to estimate premorbid baseline blood glucose concentration.
4
Higher total cholesterol, glycatedhemoglobin and insulin resistance parameters are connected with lower central dopamine tone.
5
Glucose-lowering therapies were granted regulatory approval primarily from smaller studies that have demonstrated reductions in glycatedhemoglobin concentration.
6
Top five factors in RF importance ranking were: waist, glucose, uric acid, and red cell distribution width and glycatedhemoglobin.
7
Between-group differences in blood pressure and glycatedhemoglobin levels during the trial were no longer evident by the first post-trial visit.
8
No correlation was seen between pancreatic volume index in patients and diabetes duration, glucose or C-peptide levels, glycatedhemoglobin, and islet autoantibodies.
9
The average duration of diagnosed diabetes was 10.8 years and the mean glycatedhemoglobin value was 10.8%.
10
Body mass index, blood pressure, fasting blood sugar, glycatedhemoglobin, lipid profile and antioxidants were measured at baseline and at every three months interval.
11
Aims: We describe a two-step screening approach using non-invasive risk assessment and glycatedhemoglobin (HbA1c) to identify participants for a diabetes prevention trial.
12
Individuals diagnosed with TB underwent glycatedhemoglobin (HbA1c) testing at the time of anti-tuberculous treatment initiation and at three -month follow up stage.
13
There was a trend towards greater T2D and hypertension remission rate after OAGB, while fasting glucose and glycatedhemoglobin levels were significantly lower after OAGB.
14
Changes in the glycatedhemoglobin (HbA1c) level after 3 months of treatment were compared with the baseline, and exploratory analysis was performed.
15
Glycatedhemoglobin is a measure of the patient's blood sugar control for the past two to three months.